Literature DB >> 10728677

Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island.

D J Simpson1, N A Hibberts, A M McNicol, R N Clayton, W E Farrell.   

Abstract

We recently showed loss of pRb in a proportion of pituitary tumors that was not associated with loss of heterozygosity of an RB1 intragenic marker. To further define the mechanism responsible for loss of retinoblastoma protein (pRb) expression, we have investigated the methylation status of the CpG island contained within the promoter region of the RB1 gene, together with sequence analysis of the essential promoter region and exons coding for the protein-binding pocket domain. Methylation of the CpG island within the RB1 promoter region was detected in 6 of 10 tumors that failed to express pRb. In contrast, 18 of 20 tumors and all six histologically normal postmortem pituitaries that expressed pRb were unmethylated. No inactivating mutations were found within the RB1 promoter region in the four unmethylated tumors that failed to express pRB. However, one or more exons comprising the coding region for the protein-binding pocket domain were shown to be homozygously deleted in three of four tumors available for analysis. This study describes an additional tumor type, in addition to retinoblastoma, in which methylation of the RB1 promoter is associated with loss of pRb expression. Furthermore, we show that in addition to methylation of the RB1 promoter region, deletion within the protein-binding pocket domain is associated with a loss of detectable pRb expression. The reactivation of tumor suppressor genes, silenced through methylation, represents a promising therapeutic target in sporadic pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728677

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

1.  Sequence-specific transcriptional repression by an MBD2-interacting zinc finger protein MIZF.

Authors:  Masayuki Sekimata; Yoshimi Homma
Journal:  Nucleic Acids Res       Date:  2004-01-29       Impact factor: 16.971

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Long Jin; Gail A Stilling; Heyu Zhang; Xiang Qian; Nobuki Nakamura; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

4.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

5.  Dysregulated mitogen-activated protein kinase pathway mediated cell cycle disruption in sporadic parathyroid tumors.

Authors:  A K Arya; P Singh; U N Saikia; N Sachdeva; D Dahiya; A Behera; S D Rao; S K Bhadada
Journal:  J Endocrinol Invest       Date:  2019-09-18       Impact factor: 4.256

Review 6.  Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach.

Authors:  Xun Zhang; Yunli Zhou; Anne Klibanski
Journal:  Mol Cell Endocrinol       Date:  2010-03-06       Impact factor: 4.102

7.  Aberrant CpG island methylation of multiple genes in ependymal tumors.

Authors:  M Eva Alonso; M Josefa Bello; Pilar Gonzalez-Gomez; Dolores Arjona; Jose M de Campos; Manuel Gutierrez; Juan A Rey
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Authors:  Elisabet Ognedal Berge; Stian Knappskog; Stephanie Geisler; Vidar Staalesen; Marec Pacal; Anne-Lise Børresen-Dale; Pål Puntervoll; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  Mol Cancer       Date:  2010-07-01       Impact factor: 27.401

9.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 10.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.